Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depression

Progress in Neurobiology

Volumn 91, Issue 4, 2010, Pages 275-299

  Shelton, Richard C ^a   Miller, Andrew H ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Adipocytokines; Adiposity; Cytokines; Depression; Fatty acids; Inflammation; Lipids; Obesity; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ADIPOCYTOKINE; ALPHA INTERFERON; AMITRIPTYLINE; C REACTIVE PROTEIN; CELECOXIB; CERTOLIZUMAB PEGOL; DOPAMINE; ETANERCEPT; FLUOXETINE; GOLIMUMAB; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; INTERLEUKIN 6; KYNURENINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTRANSMITTER; OMEGA 3 FATTY ACID; REBOXETINE; ROFECOXIB; SEROTONIN; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE;

ABDOMEN; ADD ON THERAPY; ADIPOCYTE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CHILDHOOD; CHRONIC INFLAMMATION; CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; EATING; ENERGY; HOPELESSNESS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE DYSREGULATION; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE; LIPID STORAGE; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEOPLASM; NERVE CELL PLASTICITY; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOARTHRITIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; PSORIASIS; REVIEW; RISK; RISK FACTOR; STRESS; UPREGULATION; WHITE ADIPOSE TISSUE; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIDEPRESSIVE AGENTS; CYTOKINES; DEPRESSION; HUMANS; INFLAMMATION; OBESITY; RISK FACTORS;

EID: 77954189887     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2010.04.004     Document Type: Review

References (369)

1. Akay A., Pekcanlar A., Bozdag K.E., Altintas L., Karaman A. Assessment of depression in subjects with psoriasis vulgaris and lichen planus. J. Eur. Acad. Dermatol. Venereol. 2002, 16:347-352.
2. Akin D., Manier D.H., Sanders-Bush E., Shelton R.C. Signal transduction abnormalities in melancholic depression. Int. J. Neuropsychopharmacol. 2005, 8:5-16.
3. Alisi A., Manco M., Panera N., Nobili V. Association between type two diabetes and non-alcoholic fatty liver disease in youth. Ann. Hepatol. 2009, 8(Suppl 1):S44-S50.
4. Amori L., Wu H.Q., Marinozzi M., Pellicciari R., Guidetti P., Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 2009, 159:196-203.
5. Amri M., Aissa S.A., Belguendouz H., Mezioug D., Touil-Boukoffa C. In vitro antihydatic action of IFN-gamma is dependent on the nitric oxide pathway. J. Interferon Cytokine Res. 2007, 27:781-787.
6. Andrei A.M., Fraguas R., Telles R.M., Alves T.C., Strunz C.M., Nussbacher A., Rays J., Iosifescu D.V., Wajngarten M. Major depressive disorder and inflammatory markers in elderly patients with heart failure. Psychosomatics 2007, 48:319-324.
7. Anforth H.R., Bluthe R.M., Bristow A., Hopkins S., Lenczowski M.J., Luheshi G., Lundkvist J., Michaud B., Mistry Y., van Dam A.M., Zhen C., Dantzer R., Poole S., Rothwell N.J., Tilders F.J., Wollman E.E. Biological activity and brain actions of recombinant rat interleukin-1alpha and interleukin-1beta. Eur. Cytokine Netw. 1998, 9:279-288.
8. Angelopoulos T.J., Lowndes J., Zukley L., Melanson K.J., Nguyen V., Huffman A., Rippe J.M. The effect of high-fructose corn syrup consumption on triglycerides and uric acid. J. Nutr. 2009, 139:1242S-1245S.
9. Antonijevic I., Murck H., Frieboes R.-M., Horn R., Brabant G., Steiger A. Elevated nocturnal profiles of serum leptin in patients with depression. J. Psych. Res. 1998, 32:403-410.
10. Astorg P., Couthouis A., Bertrais S., Arnault N., Meneton P., Guesnet P., Alessandri J.M., Galan P., Hercberg S. Association of fish and long-chain n-3 polyunsaturated fatty acid intakes with the occurrence of depressive episodes in middle-aged French men and women. Prostaglandins, Leukotrienes Ess. Fatty Acids 2008, 78:171-182.
11. Atlantis E., Baker M. Obesity effects on depression: systematic review of epidemiological studies. Int. J. Obes. (Lond.) 2008, 32:881-891.
12. Atmaca M., Kuloglu M., Tezcan E., Ustundag B., Gecici O., Firidin B. Serum leptin and cholesterol values in suicide attempters. Neuropsychobiology 2002, 45:124-127.
13. Barnes R.A., Ennis J., Schober R. Cohort analysis of Ontario suicide rates, 1877-1976. Can. J. Psych. 1986, 31:208-213.
14. Baron R.M., Kenny D.A. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J. Pers. Soc. Psychol. 1986, 51:1173-1182.
15. Basciano H., Federico L., Adeli K. Fructose, insulin resistance, and metabolic dyslipidemia. Nutr. Metab. (Lond.) 2005, 2:5.
16. Basterzi A.D., Aydemir C., Kisa C., Aksaray S., Tuzer V., Yazici K., Goka E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 2005, 20:473-476.
17. Bays H.E., Gonzalez-Campoy J.M., Bray G.A., Kitabchi A.E., Bergman D.A., Schorr A.B., Rodbard H.W., Henry R.R. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert. Rev. Cardiovasc. Ther. 2008, 6:343-368.
18. Beavers K.M., Brinkley T.E., Nicklas B.J. Effect of exercise training on chronic inflammation. Clin. Chim. Acta 2010, 411:785-793.
19. Bellentani S., Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann. Hepatol. 2009, 8(Suppl. 1):S4-S8.
20. Bengtsson B.O., Zhu J., Thorell L.H., Olsson T., Link H., Walinder J. Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats. J. Neuroimmunol. 1992, 39:109-122.
21. Ben-Sefer E., Ben-Natan M., Ehrenfeld M. Childhood obesity: current literature, policy and implications for practice. Int. Nurs. Rev. 2009, 56:166-173.
22. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., Ferstl R., von Eynatten M., Wendt T., Rudofsky G., Joswig M., Morcos M., Schwaninger M., McEwen B., Kirschbaum C., Nawroth P.P. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1920-1925.
23. Billack B. Macrophage activation: role of toll-like receptors, nitric oxide, and nuclear factor kappa B. Am. J. Pharm. Educ. 2006, 70(102):1-10.
24. Birt C., Bille-Brahe U., Cabecadas M., Chishti P., Corcoran P., Elgie R., van Heeringen K., Horte L.G., Marchi A.G., Ostamo A., Petridou E., Renberg E.S., Stone D.H., Wiik J., Williamson E. Suicide mortality in the European Union. Eur. J. Public Health 2003, 13:108-114.
25. Blakely R.D., Berson H.E. Molecular biology of serotonin receptors and transporters. Clin. Neuropharmacol. 1992, 15(Suppl. 1 Pt A):351A-352A.
26. Bluthe R.M., Laye S., Michaud B., Combe C., Dantzer R., Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur. J. Neurosci. 2000, 12:4447-4456.
27. Bluthe R.M., Michaud B., Poli V., Dantzer R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiolk. Behav. 2000, 70:367-373.
28. Bocarsly, M.E., Powell, E.S., Avena, N.M., Hoebel, B.G. High-fructose corn syrup causes characteristics of obesity in rats: Increased body weight, body fat and triglyceride levels. Pharmacol. Biochem. Behav., in press.
29. Bornstein S.R., Ehrhart-Bornstein M., Wong M.L., Licinio J. Is the worldwide epidemic of obesity a communicable feature of globalization?. Exp Clin Endocrinol Diabetes. 2008, 116(Suppl 1):S30-S32.
30. Bower J.E., Ganz P.A., Dickerson S.S., Petersen L., Aziz N., Fahey J.L. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005, 30:92-100.
31. Brandacher G., Winkler C., Aigner F., Schwelberger H., Schroecksnadel K., Margreiter R., Fuchs D., Weiss H.G. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obes. Surg. 2006, 16:541-548.
32. Bray G.A. Fructose: should we worry?. Int. J. Obes. (Lond.) 2008, 32(Suppl. 7):S127-S131.
33. Breitbart W., Rosenfeld B., Kaim M., Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch. Intern. Med. 2001, 161:411-420.
34. Breum L., Rasmussen M.H., Hilsted J., Fernstrom J.D. Twenty-four-hour plasma tryptophan concentrations and ratios are below normal in obese subjects and are not normalized by substantial weight reduction. Am. J. Clin. Nutr. 2003, 77:1112-1118.
35. Brew B.J., Halman M., Catalan J., Sacktor N., Price R.W., Brown S., Atkinson H., Clifford D.B., Simpson D., Torres G., Hall C., Power C., Marder K., Mc Arthur J.C., Symonds W., Romero C. Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. PLoS Clin. Trials 2007, 2:e13.
36. Brown C.M., Dulloo A.G., Montani J.P. Sugary drinks in the pathogenesis of obesity and cardiovascular diseases. Int. J Obes. (Lond.) 2008, 32(Suppl. 6):S28-S34.
37. Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J. Leukoc. Biol. 2005, 78:819-835.
38. Buford T.W., Cooke M.B., Shelmadine B.D., Hudson G.M., Redd L., Willoughby D.S. Effects of eccentric treadmill exercise on inflammatory gene expression in human skeletal muscle. Appl. Physiol. Nutr. Metab. 2009, 34:745-753.
39. Calabrese J.R., Skwerer R.G., Barna B., Gulledge A.D., Valenzuela R., Butkus A., Subichin S., Krupp N.E. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res. 1986, 17:41-47.
40. Calabro P., Yeh E.T. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk. Curr. Hypertens. Rep. 2008, 10:32-38.
41. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004, 56:819-824.
42. Capuron L., Fornwalt F.B., Knight B.T., Harvey P.D., Ninan P.T., Miller A.H. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. J. Affect. Disord. 2009, 119:181-185.
43. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
44. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., Miller A.H. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54:906-914.
45. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007, 32:2384-2392.
46. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am. J. Psychiatry 2003, 160:1342-1345.
47. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
48. Carr M.W., Roth S.J., Luther E., Rose S.S., Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:3652-3656.
49. Cartier A., Bergeron J., Poirier P., Almeras N., Tremblay A., Lemieux I., Despres J.P. Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity. Ann. Med. 2009, 1-8.
50. Chiarelli F., Marcovecchio M.L. Insulin resistance and obesity in childhood. Eur. J. Endocrinol. 2008, 159(Suppl. 1):S67-S74.
51. Chrysohoou C., Panagiotakos D.B., Pitsavos C., Das U.N., Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The Attica study. J. Am. Coll. Cardiol. 2004, 44:152-158.
52. Church T. The low-fitness phenotype as a risk factor: More than just being sedentary?. Obesity 2009, 17:S39-S42.
53. Collantes-Estevez E., Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Curr. Med. Res. Opin. 2003, 19:402-410.
54. Connor T.J., Starr N., O'Sullivan J.B., Harkin A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?. Neurosci. Lett. 2008, 441:29-34.
55. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., Ohannesian J.P., Marco C.C., McKee L.J., Bauer T.L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996, 334:292-295.
56. Cook D.N., Pisetsky D.S., Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 2004, 5:975-979.
57. Cumurcu B.E., Ozyurt H., Etikan I., Demir S., Karlidag R. Total antioxidant capacity and total oxidant status in patients with major depression: Impact of antidepressant treatment. Psychiatry Clin. Neurosci. 2009, 63:639-645.
58. Dai J., Miller A.H., Bremner J.D., Goldberg J., Jones L., Shallenberger L., Buckham R., Murrah N.V., Veledar E., Wilson P.W., Vaccarino V. Adherence to the Mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: A twin study. Circulation 2008, 117:169-175.
59. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111:1448-1454.
60. Danese A., Moffitt T.E., Harrington H., Milne B.J., Polanczyk G., Pariante C.M., Poulton R., Caspi A. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch. Pediatr. Adolesc. Med. 2009, 163:1135-1143.
61. Dantzer R. Cytokine, sickness behavior, and depression. Immunol. Allergy Clin. North Am. 2009, 29:247-264.
62. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 2007, 21:153-160.
63. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
64. Dauden E., Griffiths C., Ortonne J.P., Kragballe K., Molta C., Robertson D., Pedersen R., Estojak J., Boggs R. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J. Eur. Acad. Dermatol. Venereol. 2009, 23:1374-1382.
65. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 1990, 47:411-418.
66. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Heninger G.R., Gelenberg A.J., Charney D.S. Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. 1993, 29:389-396.
67. Delgado P.L., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Moreno F.A., Heninger G.R., Charney D.S. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 1999, 46:212-220.
68. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Aghajanian G.K., Heninger G.R., Charney D.S. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch. Gen. Psychiatry 1994, 51:865-874.
69. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Heninger G.R., Charney D.S. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol. Bull. 1991, 27:321-330.
70. DeRijk R., Michelson D., Karp B., Petrides J., Galliven E., Deuster P., Paciotti G., Gold P.W., Sternberg E.M. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1beta (IL-beta), IL-6, and tumor necrosis factor-alpha (TNFalpha) production in humans: High sensitivity of TNFalpha and resistance of IL-6. J. Clin. Endocrinol. Metab. 1997, 82:2182-2191.
71. Despres J.P., Arsenault B.J., Cote M., Cartier A., Lemieux I. Abdominal obesity: the cholesterol of the 21st century?. Can. J. Cardiol. 2008, 24(Suppl. D):7D-12D.
72. Deuschle M., Blum W.F., Englaro P., Schweiger U., Weber B., Pflaum C.D., Heuser I. Plasma leptin in depressed patients and healthy controls. Horm. Metab. Res. 1996, 28:714-717.
73. D'Mello C., Le T., Swain M.G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J. Neurosci. 2009, 29:2089-2102.
74. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
75. Duman R.S., Malberg J., Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 1999, 46:1181-1191.
76. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
77. Ehses J.A., Lacraz G., Giroix M.H., Schmidlin F., Coulaud J., Kassis N., Irminger J.C., Kergoat M., Portha B., Homo-Delarche F., Donath M.Y. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13998-14003.
78. Eickelberg O., Roth M., Lorx R., Bruce V., Rudiger J., Johnson M., Block L.H. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J. Biol. Chem. 1999, 274:1005-1010.
79. Enerback S. The origins of brown adipose tissue. N. Engl. J. Med. 2009, 360:2021-2023.
80. Esposito K., Marfella R., Ciotola M., Di Palo C., Giugliano F., Giugliano G., D'Armiento M., D'Andrea F., Giugliano D. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: A randomized trial. JAMA 2004, 292:1440-1446.
81. Estruch R., Martínez-González M., Corella D., Salas-Salvadó J., Ruiz-Gutiérrez V., Covas M.I., Fiol M., Gómez-Gracia E., López-Sabater M.C., Vinyoles E., Arós F., Conde M., Lahoz C., Lapetra J., Sáez G., Ros E. Effects of a Mediterranean-Style diet on cardiovascular risk factors. Ann. Int. Med. 2006, 145:1-11.
82. Eyzaguirre F., Mericq V. Insulin resistance markers in children. Horm. Res. 2009, 71:65-74.
83. Fain J.N. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam. Horm. 2006, 74:443-477.
84. Feigin A., Fukuda M., Dhawan V., Przedborski S., Jackson-Lewis V., Mentis M.J., Moeller J.R., Eidelberg D. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001, 57:2083-2088.
85. Feldman S.R., Gottlieb A.B., Bala M., Wu Y., Eisenberg D., Guzzo C., Li S., Dooley L.T., Menter A. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br. J. Dermatol. 2008, 159:704-710.
86. Felger J.C., Alagbe O., Hu F., Mook D., Freeman A.A., Sanchez M.M., Kalin N.H., Ratti E., Nemeroff C.B., Miller A.H. Effects of interferon-alpha on Rhesus Monkeys: A nonhuman primate model of cytokine-induced depression. Biol. Psychiatry 2007, 62:1324-1333.
87. Feve B., Bastard J.P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2009, 5:305-311.
88. Figlewicz D.P., Ioannou G., Bennett J.J., Kittleson S., Savard C., Roth C.L. Effect of moderate intake of sweeteners on metabolic health in the rat. Physiol. Behav. 2009, 98:618-624.
89. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research, New York State Psychiatric Institute: New York, NY.
90. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
91. Frangou S., Lewis M., McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br. J. Psychiatry 2006, 188:46-50.
92. Freeman M.P., Hibbeln J.R., Wisner K.L., Davis J.M., Mischoulon D., Peet M., Keck P.E., Marangell L.B., Richardson A.J., Lake J., Stoll A.L. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J. Clin. Psychiatry 2006, 67:1954-1967.
93. Frosig C., Richter E.A. Improved insulin sensitivity after exercise: focus on insulin signaling. Obesity 2009, 17:S15-S20.
94. Fruhbeck G. Overview of adipose tissue and its role in obesity and metabolic disorders. Methods Mol. Biol. 2008, 456:1-22.
95. Fujiwara K., Mori K., Kaneko Y.S., Nakashima A., Nagasaka A., Itoh M., Ota A. Tetrahydrobiopterin biosynthesis in white and brown adipose tissues is enhanced following intraperitoneal administration of bacterial lipopolysaccharide. Biochim. Biophys. Acta 2004, 1670:181-198.
96. Galli C., Calder P.C. Effects of fat and fatty acid intake on inflammatory and immune responses: a critical review. Ann. Nutr. Metab. 2009, 55:123-139.
97. Gilchrist M., Hesslinger C., Befus A.D. Tetrahydrobiopterin, a critical factor in the production and role of nitric oxide in mast cells. J. Biol. Chem. 2003, 278:50607-50614.
98. Gillespie C.F., Nemeroff C.B. Hypercortisolemia and depression. Psychosom. Med. 2005, 67(Suppl 1):S26-S28.
99. Gleason O.C., Fucci J.C., Yates W.R., Philipsen M.A. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C-A pilot study. Dig. Dis. Sci. 2007, 52:2557-2563.
100. Gold P.W., Chrousos G.P. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol. Psychiatry 2002, 7:254-275.
101. Gold S.M., Irwin M.R. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Neurol. Clin. 2006, 24:507-519.
102. Golden S.H., Robinson K.A., Saldanha I., Anton B., Ladenson P.W. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin. Endocrinol. Metab. 2009, 94:1853-1878.
103. Goodwin R.D., Sourander A., Duarte C.S., Niemela S., Multimaki P., Nikolakaros G., Helenius H., Piha J., Kumpulainen K., Moilanen I., Tamminen T., Almqvist F. Do mental health problems in childhood predict chronic physical conditions among males in early adulthood? Evidence from a community-based prospective study. Psychol. Med. 2009, 39:301-311.
104. Grinevich V., Harbuz M., Ma X.M., Jessop D., Tilders F.J., Lightman S.L., Aguilera G. Hypothalamic pituitary adrenal axis and immune responses to endotoxin in rats with chronic adjuvant-induced arthritis. Exp. Neurol. 2002, 178:112-123.
105. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
106. Guillemin G.J., Kerr S.J., Brew B.J. Involvement of quinolinic acid in AIDS dementia complex. Neurotox. Res. 2005, 7:103-123.
107. Guo J.Y., Li C.Y., Ruan Y.P., Sun M., Qi X.L., Zhao B.S., Luo F. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur. J. Pharmacol. 2009, 612:54-60.
108. Hamer M., Molloy G.J., de Oliveira C., Demakakos P. Leisure time physical activity, risk of depressive symptoms, and inflammatory mediators: The English Longitudinal Study of Ageing. Psychoneuroendocrinology 2009, 34:1050-1055.
109. Hamer M., Molloy G.J., de O.C., Demakakos P. Persistent depressive symptomatology and inflammation: to what extent do health behaviours and weight control mediate this relationship?. Brain Behav. Immun. 2009, 23:413-418.
110. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
111. Hansson G.K., Edfeldt K. Toll to be paid at the gateway to the vessel wall. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1085-1087.
112. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
113. Hart B.L. Biological basis of the behavior of sick animals. Neurosci. Biobehav. Rev. 1988, 12:123-137.
114. Hasler G., Pine D.S., Gamma A., Milos G., Ajdacic V., Eich D., Rossler W., Angst J. The associations between psychopathology and being overweight: a 20-year prospective study. Psychol. Med. 2004, 34:1047-1057.
115. Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., Gulati M., Thornton A.J., Schultz R.L., Valentine A.D., Meyers C.A., Howell C.D. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 2002, 7:942-947.
116. Heim C., Nemeroff C.B. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol. Psychiatry 2001, 49:1023-1039.
117. Heim C., Newport D.J., Mletzko T., Miller A.H., Nemeroff C.B. The link between childhood trauma and depression: Insights from HPA axis studies in humans. Psychoneuroendocrinology 2008, 33:693-710.
118. Hestad K.A., Tonseth S., Stoen C.D., Ueland T., Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J. ECT 2003, 19:183-188.
119. Hevener, A.L., Febbraio, M.A. The 2009 Stock Conference Report: Inflammation, obesity and metabolic disease. Obes. Rev., in press.
120. Hilsman R., Garber J. A test of the cognitive diathesis-stress model of depression in children: academic stressors, attributional style, perceived competence, and control. J. Personality Soc. Psychol. 1995, 69:370-380.
121. Howren M.B., Lamkin D.M., Suls J. Associations of depression with c-reactive protein, il-1, and il-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
122. Hu F., Pace T.W., Miller A.H. Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells. Brain Behav. Immun. 2009, 23:455-463.
123. Hughes M.N. Chemistry of nitric oxide and related species. Methods Enzymol. 2008, 436:3-19.
124. Illman J., Corringham R., Robinson D., Davis H.M., Rossi J.F., Cella D., Trikha M. Are inflammatory cytokines the common link between cancer-associated cachexia and depression?. J. Support. Oncol. 2005, 3:37-50.
125. Irwin M.R., Miller A.H. Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav. Immun. 2007, 21:374-383.
126. IUPAC-IUB Commission on Biochemical Nomenclature 1978. The nomenclature of lipids (recommendations 1976). J. Lipid Res. 19, 114-128.
127. Jacobson C.M., Rosenfeld B., Pessin H., Breitbart W. Depression and IL-6 blood plasma concentrations in advanced cancer patients. Psychosomatics 2008, 49:64-66.
128. James W.P. The epidemiology of obesity: the size of the problem. J. Intern. Med. 2008, 263:336-352.
129. Jang S., Jeong H.S., Park J.S., Kim Y.S., Jin C.Y., Seol M.B., Kim B.C., Lee M.C. Neuroprotective effects of (-)-epigallocatechin-3-gallate against quinolinic acid-induced excitotoxicity via PI3K pathway and NO inhibition. Brain Res. 2010, 11313C:25-33.
130. Janiszewski P.M., Ross R. The utility of physical activity in the management of global cardiometabolic risk. Obesity 2009, 17:S3-S14.
131. Jeffery A.N., Murphy M.J., Metcalf B.S., Hosking J., Voss L.D., English P., Sattar N., Wilkin T.J. Adiponectin in childhood. Int. J. Pediatr. Obes. 2008, 3:130-140.
132. Jehn C.F., Kuehnhardt D., Bartholomae A., Pfeiffer S., Krebs M., Regierer A.C., Schmid P., Possinger K., Flath B.C. Biomarkers of depression in cancer patients. Cancer 2006, 107:2723-2729.
133. Jow G.M., Yang T.T., Chen C.L. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J. Affect. Disord. 2006, 90:21-27.
134. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., Bauer J., Lieb K. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000, k152:383-389.
135. Juge-Aubry C.E., Somm E., Giusti V., Pernin A., Chicheportiche R., Verdumo C., Rohner-Jeanrenaud F., Burger D., Dayer J.M., Meier C.A. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003, 52:1104-1110.
136. Juge-Aubry C.E., Somm E., Pernin A., Alizadeh N., Giusti V., Dayer J.M., Meier C.A. Adipose tissue is a regulated source of interleukin-10. Cytokine 2005, 29:270-274.
137. Juturu V. Omega-3 fatty acids and the cardiometabolic syndrome. J. Cardiometab. Syndr. 2008, 3:244-253.
138. Kaestner F., Hettich M., Peters M., Sibrowski W., Hetzel G., Ponath G., Arolt V., Cassens U., Rothermundt M. Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity. J. Affect. Disord. 2005, 87:305-311.
139. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K.i., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116:1494-1505.
140. Kekow J., Moots R.J., Emery P., Durez P., Koenig A., Singh A., Pedersen R., Robertson D., Freundlich B., Sato R. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann. Rheum. Dis. 2010, 69:222-225.
141. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17(Suppl. 1):S112-S118.
142. Kennaugh J.M., Hay W.W. Nutrition of the fetus and newborn. West. J. Med. 1987, 147:435-448.
143. Kitagami T., Yamada K., Miura H., Hashimoto R., Nabeshima T., Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res. 2003, 978:104-114.
144. Klerman G.L., Lavori P.W., Rice J., Reich T., Endicott J., Andreasen N.C., Keller M.B., Hirschfield R.M. Birth-cohort trends in rates of major depressive disorder among relatives of patients with affective disorder. Arch. Gen. Psychiatry 1985, 42:689-693.
145. Korner A., Kratzsch J., Gausche R., Schaab M., Erbs S., Kiess W. New predictors of the metabolic syndrome in children--role of adipocytokines. Pediatr. Res. 2007, 61:640-645.
146. Kozak L.P., Britton J.H., Kozak U.C., Wells J.M. The mitochondrial uncoupling protein gene. Correlation of exon structure to transmembrane domains. J. Biol. Chem. 1988, 263:12274-12277.
147. Kraguljac N.V., Montori V.M., Pavuluri M., Chai H.S., Wilson B.S., Unal S.S. Efficacy of omega-3 Fatty acids in mood disorders - a systematic review and metaanalysis. Psychopharmacol. Bull. 2009, 42:39-54.
148. Kraus M.R., Schafer A., Schottker K., Keicher C., Weissbrich B., Hofbauer I., Scheurlen M. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008, 57:531-536.
149. Kraus T., Haack M., Schuld A., Hinze-Selch D., Pollm+ñcher T. Low leptin levels but norma body mass indices in patients with depression or schizophrenia. Neuroendocrinology 2001, 73:243-247.
150. Krishnan R., Cella D., Leonardi C., Papp K., Gottlieb A.B., Dunn M., Chiou C.F., Patel V., Jahreis A. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br. J. Dermatol. 2007, 157:1275-1277.
151. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001, 137:280-284.
152. Kubera M., Kenis G., Bosmans E., Jaworska-Feil L., Lason W., Scharpe S., Maes M. Suppressive effect of TRH and imipramine on human interferon-gamma and interleukin-10 production in vitro. Pol. J. Pharmacol. 2000, 52:481-486.
153. Kubera M., Kenis G., Bosmans E., Zieba A., Dudek D., Nowak G., Maes M. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol. 2000, 52:237-241.
154. Kubera M., Lin A.H., Kenis G., Bosmans E., van B.D., Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J. Clin. Psychopharmacol. 2001, 21:199-206.
155. Kubera M., Maes M., Holan V., Basta-Kaim A., Roman A., Shani J. Prolonged desipramine treatment increases the production of interleukin-10, an anti-inflammatory cytokine, in C57BL/6 mice subjected to the chronic mild stress model of depression. J. Affect. Disord. 2001, 63:171-178.
156. Kubera M., Simbirtsev A., Mathison R., Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 2000, 96:255-266.
157. Kumar R., Thompson E.B. Gene regulation by the glucocorticoid receptor: structure:function relationship. J. Steroid Biochem. Mol. Biol. 2005, 94:383-394.
158. Kumari B., Kumar A., Dhir A. Protective effect of non-selective and selective COX-2-inhibitors in acute immobilization stress-induced behavioral and biochemical alterations. Pharmacol. Rep. 2007, 59:699-707.
159. Kwidzinski E., Bechmann I. IDO expression in the brain: a double-edged sword. J. Mol. Med. 2007, 85:1351-1359.
160. Lago F., Dieguez C., Gomez-Reino J., Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat. Clin. Pract. Rheumatol. 2007, 3:716-724.
161. Lago F., Gomez R., Gomez-Reino J.J., Dieguez C., Gualillo O. Adipokines as novel modulators of lipid metabolism. Trends Biochem. Sci. 2009, 34:500-510.
162. Laguno M., Blanch J., Murillas J., Blanco J.L., Leon A., Lonca M., Larrousse M., Biglia A., Martinez E., Garcia F., Miro J.M., de P.J., Gatell J.M., Mallolas J. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir. Ther. 2004, 9:905-909.
163. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
164. Lara-Castro C., Fu Y., Chung B.H., Garvey W.T. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr. Opin. Lipidol. 2007, 18:263-270.
165. Larsen C.M., Faulenbach M., Vaag A., Ehses J.A., Donath M.Y., Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diab. Care 2009, 32:1663-1668.
166. Lavori P.W., Warshaw M., Klerman G., Mueller T.I., Leon A., Rice J., Akiskal H. Secular trends in lifetime onset of MDD stratified by selected sociodemographic risk factors. J. Psychiatr. Res 1993, 27:95-109.
167. Levenson J.L., Fallon H.J. Fluoxetine treatment of depression caused by interferon-alpha. Am. J. Gastroenterol. 1993, 88:760-761.
168. Levine J., Barak Y., Chengappa K.N., Rapoport A., Rebey M., Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40:171-176.
169. Li W., Knowlton D., Woodward W.R., Habecker B.A. Regulation of noradrenergic function by inflammatory cytokines and depolarization. J. Neurochem. 2003, 86:774-783.
170. Lichtenstein G.R., Bala M., Han C., DeWoody K., Schaible T. Infliximab improves quality of life in patients with Crohn's disease. Inflamm. Bowel. Dis. 2002, 8:237-243.
171. Linnoila M., Whorton A.R., Rubinow D.R., Cowdry R.W., Ninan P.T., Waters R.N. CSF prostaglandin levels in depressed and schizophrenic patients. Arch. Gen. Psychiatry 1983, 40:405-406.
172. Livija D., Barbara B., Cecilia G., Yeny Martinez de la Torre, Alberto M. Pentraxins: Multifunctional proteins at the interface of innate immunity and inflammation. BioFactors 2009, 35:138-145.
173. Loftis J.M., Socherman R.E., Howell C.D., Whitehead A.J., Hill J.A., Dominitz J.A., Hauser P. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci. Lett. 2004, 365:87-91.
174. Lolait S.J., Stewart L.Q., Jessop D.S., Young W.S., O'Carroll A.M. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 2007, 148:849-856.
175. Lou J.S., Kearns G., Benice T., Oken B., Sexton G., Nutt J. Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study. Mov. Disord. 2003, 18:1108-1114.
176. Lu X.Y. The leptin hypothesis of depression: a potential link between mood disorders and obesity?. Curr. Opin. Pharmacol. 2007, 7:648-652.
177. Lu X.Y., Kim C.S., Frazer A., Zhang W. Leptin: a potential novel antidepressant. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1593-1598.
178. Luppino F.S., de Wit L.M., Bouvy P.F., Stijnen T., Cuijpers P., Penninx B.W.J.H., Zitman F.G. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch. Gen. Psychiatry 2010, 67:220-229.
179. Lutgendorf S.K., Weinrib A.Z., Penedo F., Russell D., DeGeest K., Costanzo E.S., Henderson P.J., Sephton S.E., Rohleder N., Lucci J.A., Cole S., Sood A.K., Lubaroff D.M. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol. 2008, 26:4820-4827.
180. Maas J.W. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Arch. Gen. Psychiatry 1975, 32:1357-1361.
181. Maas J.W. Clinical and biochemical heterogeneity of depressive disorders. Ann. Intern. Med. 1978, 88:556-563.
182. MacPhee M. Global childhood obesity: how to curb an epidemic. J. Pediatr. Nurs. 2008, 23:1-4.
183. Maes M. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Minireview. Neuro. Endocrinol. Lett. 2008, 29:287-291.
184. Maes M., Mihaylova I., Kubera M., Bosmans E. Why fish oils may not always be adequate treatments for depression or other inflammatory illnesses: docosahexaenoic acid, an omega-3 polyunsaturated fatty acid, induces a Th-1-like immune response. Neuro. Endocrinol. Lett. 2007, 28:875-880.
185. Maes M., Song C., Lin A.H., Bonaccorso S., Kenis G., De J.R., Bosmans E., Scharpe S. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999, 20:370-379.
186. Majer M., Welberg L.A., Capuron L., Pagnoni G., Raison C.L., Miller A.H. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav. Immun. 2008, 22:870-880.
187. Manier D.H., Eiring A., Shelton R.C., Sulser F. Beta-adrenoceptor-linked protein kinase A (PKA) activity in human fibroblasts from normal subjects and from patients with major depression. Neuropsychopharmacology 1996, 15:555-561.
188. Marques-Vidal, P., Pecoud, A., Hayoz, D., Paccaud, F., Mooser, V., Waeber, G., and Vollenweider, P. Normal weight obesity: Relationship with lipids, glycaemic status, liver enzymes and inflammation. Nutr. Metab. Cardiovasc. Dis., in press.
189. Marriott B.P., Cole N., Lee E. National estimates of dietary fructose intake increased from 1977 to 2004 in the United States. J. Nutr. 2009, 139:1228S-1235S.
190. Mathieu P., Poirier P., Pibarot P., Lemieux I., Despres J.P. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009, 53:577-584.
191. Matrisciano F., Bonaccorso S., Ricciardi A., Scaccianoce S., Panaccione I., Wang L., Ruberto A., Tatarelli R., Nicoletti F., Girardi P., Shelton R.C. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine. J. Psychiatr. Res. 2009, 43:247-254.
192. Matsuki T., Horai R., Sudo K., Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. 2003, 198:877-888.
193. Maughan B., Iervolino A.C., Collishaw S. Time trends in child and adolescent mental disorders. Curr. Opin. Psychiatry 2005, 18:381-385.
194. Mazza M., Pomponi M., Janiri L., Bria P., Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 2007, 31:12-26.
195. McElroy S.L., Kotwal R., Malhotra S., Nelson E.B., Keck P.E., Nemeroff C.B. Are mood disorders and obesity related? A review for the mental health professional. J. Clin. Psychiatry 2004, 65:634-651.
196. McKay L.I., Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev. 1999, 20:435-459.
197. McMurray R.G., Zaldivar F., Galassetti P., Larson J., Eliakim A., Nemet D., Cooper D.M. Cellular immunity and inflammatory mediator responses to intense exercise in overweight children and adolescents. J. Investig. Med. 2007, 55:120-129.
198. McVean J.J., Carrel A.L., Eickhoff J.C., Allen D.B. Fitness level and body composition are associated with inflammation in non-obese children. J. Pediatr. Endocrinol. Metab. 2009, 22:153-159.
199. Meier C.A., Bobbioni E., Gabay C., Assimacopoulos-Jeannet F., Golay A., Dayer J.M. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?. J. Clin. Endocrinol. Metab. 2002, 87:1184-1188.
200. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int. Clin. Psychopharmacol. 2006, 21:227-231.
201. Menzies H., Chochinov H.M., Breitbart W. Cytokines, cancer and depression: connecting the dots. J. Support. Oncol. 2005, 3:55-57.
202. Miettola J., Niskanen L.K., Viinamaki H., Kumpusalo E. Metabolic syndrome is associated with self-perceived depression. Scand. J. Prim. Health Care 2008, 26:203-210.
203. Miller A.H. Mechanisms of cytokine-induced behavioral changes: Psychoneuroimmunology at the translational interface. Brain Behav. Immun. 2009, 23:149-158.
204. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
205. Miller G.E., Freedland K.E., Carney R.M., Stetler C.A., Banks W.A. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav. Immun. 2003, 17:276-285.
206. Miller G.E., Freedland K.E., Duntley S., Carney R.M. Relation of depressive symptoms to C-reactive protein and pathogen burden (cytomegalovirus, herpes simplex virus, Epstein-Barr virus) in patients with earlier acute coronary syndromes. Am. J. Cardiol. 2005, 95:317-321.
207. Miller G.E., Stetler C.A., Carney R.M., Freedland K.E., Banks W.A. Clinical depression and inflammatory risk markers for coronary heart disease. Am. J. Cardiol. 2002, 90:1279-1283.
208. Miller Y.I., Viriyakosol S., Worrall D.S., Boullier A., Butler S., Witztum J.L. Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1213-1219.
209. Mischoulon D. Update and Critique of natural remedies as antidepressant treatments. Obstetrics Gynecol. Clin. North Am. 2009, 36:789-807.
210. Mischoulon D., Papakostas G.I., Dording C.M., Farabaugh A.H., Sonawalla S.B., Agoston A.M., Smith J., Beaumont E.C., Dahan L.E., Alpert J.E., Nierenberg A.A., Fava M. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J. Clin. Psychiatry 2010, 70:1636-1644.
211. Mohr D.C., Goodkin D.E., Islar J., Hauser S.L., Genain C.P. Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis. Arch. Neurol. 2001, 58:1081-1086.
212. Molleston J.P., White F., Teckman J., Fitzgerald J.F. Obese children with steatohepatitis can develop cirrhosis in childhood. Am. J. Gastroenterol. 2002, 97:2460-2462.
213. Montecino-Rodriguez E., Dorshkind K. New perspectives in B-1 B cell development and function. Trends Immunol. 2006, 27:428-433.
214. Moran T.H. Fructose and satiety. J. Nutr. 2009, 139:1253S-1256S.
215. Morasco B.J., Rifai M.A., Loftis J.M., Indest D.W., Moles J.K., Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J. Affect. Disord. 2007, 103:83-90.
216. Moron J.A., Zakharova I., Ferrer J.V., Merrill G.A., Hope B., Lafer E.M., Lin Z.C., Wang J.B., Javitch J.A., Galli A., Shippenberg T.S. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J. Neurosci. 2003, 23:8480-8488.
217. Mosley R.L., Benner E.J., Kadiu I., Thomas M., Boska M.D., Hasan K., Laurie C., Gendelman H.E. Neuroinflammation, oxidative stress and the pathogenesis of parkinson's disease. Clin. Neurosci. Res. 2006, 6:261-281.
218. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
219. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol. Psychiatry 2006, 11:680-684.
220. Murphy J.M., Horton N.J., Burke J.D., Monson R.R., Laird N.M., Lesage A., Sobol A.M. Obesity and weight gain in relation to depression: findings from the Stirling County Study. Int. J. Obes. (Lond.) 2009, 33:335-341.
221. Murphy S.P. The state of the science on dietary sweeteners containing fructose: summary and issues to be resolved. J. Nutr. 2009, 139:1269S-1270S.
222. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344:961-966.
223. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 2001, 158:1252-1257.
224. Muzzin P. The uncoupling proteins. Ann. Endocrinol. (Paris) 2002, 63:106-110.
225. Myint A.M., Leonard B.E., Steinbusch H.W., Kim Y.K. Th1, Th2, and Th3 cytokine alterations in major depression. J. Affect. Disord. 2005, 88:167-173.
226. Myint A.M., Steinbusch H.W., Goeghegan L., Luchtman D., Kim Y.K., Leonard B.E. Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in an olfactory bulbectomised rat model of depression. Neuroimmunomodulation 2007, 14:65-71.
227. Nakao M., Yano E. Relationship between major depression and high serum cholesterol in Japanese men. Tohoku J. Exp. Med. 2004, 204:273-287.
228. Nanda K. Non-alcoholic steatohepatitis in children. Pediatr. Transplant. 2004, 8:613-618.
229. Nathan C., Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8841-8848.
230. NCEP expert panel 2001. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285, 2486-2497.
231. NCEP Expert Panel 2002. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421.
232. Nemets B., Stahl Z., Belmaker R.H. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry 2002, 159:477-479.
233. Nemets H., Nemets B., Apter A., Bracha Z., Belmaker R.H. Omega-3 treatment of childhood depression: A controlled, double-blind pilot study. Am. J. Psychiatry 2006, 163:1098-1100.
234. Nestler E.J., Terwilliger R.Z., Duman R.S. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J. Neurochem. 1989, 53:1644-1647.
235. Nguyen M.D., Julien J.P., Rivest S. Innate immunity: the missing link in neuroprotection and neurodegeneration?. Nat. Rev. Neurosci. 2002, 3:216-227.
236. Nicholls D.G., Bernson V.S., Heaton G.M. The identification of the component in the inner membrane of brown adipose tissue mitochondria responsible for regulating energy dissipation. Experientia Suppl. 1978, 32:89-93.
237. Nishino S., Ueno R., Ohishi K., Sakai T., Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression. Am. J. Psychiatry 1989, 146:365-368.
238. Obuchowicz E., Kowalski J., Labuzek K., Krysiak R., Pendzich J., Herman Z.S. Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures. Int. J. Neuropsychopharmacol. 2006, 9:27-35.
239. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
240. Ohishi K., Ueno R., Nishino S., Sakai T., Hayaishi O. Increased level of salivary prostaglandins in patients with major depression. Biol. Psychiatry 1988, 23:326-334.
241. Olszanecka-Glinianowicz, M., Zahorska-Markiewicz, B., Kocelak, P., Janowska, J., Semik-Grabarczyk, E., Wikarek, T., Gruszka, W., Dabrowski, P. Is chronic inflammation a possible cause of obesity-related depression? Mediators. Inflamm., in press.
242. Owe-Young R., Webster N.L., Mukhtar M., Pomerantz R.J., Smythe G., Walker D., Armati P.J., Crowe S.M., Brew B.J. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. J. Neurochem. 2008, 105:1346-1357.
243. Pace T.W., Miller A.H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci. 2009, 1179:86-105.
244. Pace T.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: Relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21:9-19.
245. Pace T.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 2007, 21:9-19.
246. Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., Heim C.M. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 2006, 163:1630-1633.
247. Pan A., Ye X., Franco O.H., Li H., Yu Z., Wang J., Qi Q., Gu W., Pang X., Liu H., Lin X. The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese. PLoS One 2008, 3:e1392.
248. Panagiotakos D.B., Tzima N., Pitsavos C., Chrysohoou C., Zampelas A., Toussoulis D., Stefanadis C. The association between adherence to the Mediterranean diet and fasting indices of glucose homoeostasis: The ATTICA Study. J. Am. Coll. Nutr. 2007, 26:32-38.
249. Pandey G.N., Dwivedi Y., Ren X., Rizavi H.S., Mondal A.C., Shukla P.K., Conley R.R. Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. Neuropsychopharmacology 2005, 30:1548-1556.
250. Pandey G.N., Dwivedi Y., Ren X., Rizavi H.S., Roberts R.C., Conley R.R. Cyclic AMP response element-binding protein in post-mortem brain of teenage suicide victims: specific decrease in the prefrontal cortex but not the hippocampus. Int. J. Neuropsychopharmacol. 2007, 10:621-629.
251. Pariante C.M., Nemeroff C.B., Miller A.H. Glucocorticoid receptors in depression. Isr. J. Med. Sci. 1995, 31:705-712.
252. Parul T., Prashant T., Luv K., Vinod S. The role of nitric oxide in inflammatory reactions. FEMS Immunol. Med. Microbiol. 2007, 51:443-452.
253. Peet M., Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry 2002, 59:913-919.
254. Penuelas I., Encio I.J., Lopez-Moratalla N., Santiago E. cAMP activates transcription of the human glucocorticoid receptor gene promoter. J. Steroid Biochem. Mol. Biol. 1998, 67:89-94.
255. Ploeger H.E., Takken T., de Greef M.H., Timmons B.W. The effects of acute and chronic exercise on inflammatory markers in children and adults with a chronic inflammatory disease: a systematic review. Exerc. Immunol. Rev. 2009, 15:6-41.
256. Plotsky P.M., Owens M.J., Nemeroff C.B. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr. Clin. North Am. 1998, 21:293-307.
257. Pollak Y., Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int. J. Neuropsychopharmacol. 2002, 5:389-399.
258. Popov A., Abdullah Z., Wickenhauser C., Saric T., Driesen J., Hanisch F.G., Domann E., Raven E.L., Dehus O., Hermann C., Eggle D., Debey S., Chakraborty T., Kronke M., Utermohlen O., Schultze J.L. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J. Clin. Invest. 2006, 116:3160-3170.
259. Pratt W.B., Morishima Y., Murphy M., Harrell M. Chaperoning of glucocorticoid receptors. Handb. Exp. Pharmacol. 2006, 172:111-138.
260. Pulkki-Raback L., Elovainio M., Kivimaki M., Mattsson N., Raitakari O.T., Puttonen S., Marniemi J., Viikari J.S., Keltikangas-Jarvinen L. Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. Health Psychol. 2009, 28:108-116.
261. Pusztai L., Mendoza T.R., Reuben J.M., Martinez M.M., Willey J.S., Lara J., Syed A., Fritsche H.A., Bruera E., Booser D., Valero V., Arun B., Ibrahim N., Rivera E., Royce M., Cleeland C.S., Hortobagyi G.N. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004, 25:94-102.
262. Quan N., Banks W.A. Brain-immune communication pathways. Brain Behav. Immun. 2007, 21:727-735.
263. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
264. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
265. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-[alpha] effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry 2010, 15:535-547.
266. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
267. Raison C.L., Woolwine B.J., Demetrashvili M.F., Borisov A.S., Weinreib R., Staab J.P., Zajecka J.M., Bruno C.J., Henderson M.A., Reinus J.F., Evans D.L., Asnis G.M., Miller A.H. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment. Pharmacol. Ther. 2007, 25:1163-1174.
268. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci. 2008, 11:81s-110s.
269. Rassoulpour A., Wu H.Q., Ferre S., Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 2005, 93:762-765.
270. Reeves G.M., Postolache T.T., Snitker S. Childhood obesity and depression: connection between these growing problems in growing children. Int. J. Child. Health Hum. Dev. 2008, 1:103-114.
271. Rich T., Innominato P.F., Boerner J., Mormont M.C., Iacobelli S., Baron B., Jasmin C., Levi F. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11:1757-1764.
272. Rivenes A.C., Harvey S.B., Mykletun A. The relationship between abdominal fat, obesity, and common mental disorders: Results from the HUNT Study. J. Psychosom. Res. 2009, 66:269-275.
273. Roberts E.A. Nonalcoholic steatohepatitis in children. Curr. Gastroenterol. Rep. 2003, 5:253-259.
274. Rogatsky I., Ivashkiv L.B. Glucocorticoid modulation of cytokine signaling. Tissue Antigens 2006, 68:1-12.
275. Romanovsky A.A., Almeida M.C., Aronoff D.M., Ivanov A.I., Konsman J.P., Steiner A.A., Turek V.F. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front. Biosci. 2005, 10:2193-2216.
276. Rubin R.T., Rhodes M.E., Czambel R.K. Sexual diergism of baseline plasma leptin and leptin suppression by arginine vasopressin in major depressives and matched controls. Psychiatry Res. 2002, 113:255-268.
277. Ruxton C.H., Reed S.C., Simpson M.J., Millington K.J. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J. Hum. Nutr. Diet. 2004, 17:449-459.
278. Sacheck J. Pediatric obesity: an inflammatory condition?. JPEN J. Parenter. Enteral Nutr. 2008, 32:633-637.
279. Salamone J.D., Correa M. Dopamine/adenosine interactions involved in effort-related aspects of food motivation. Appetite 2009, 53:422-425.
280. Salas-Salvado J., Fernandez-Ballart J., Ros E., Martinez-Gonzalez M.A., Fito M., Estruch R., Corella D., Fiol M., Gomez-Gracia E., Aros F., Flores G., Lapetra J., Lamuela-Raventos R., Ruiz-Gutierrez V., Bullo M., Basora J., Covas M.I. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. Arch. Intern. Med. 2008, 168:2449-2458. and for the PREDIMED Study Investigators.
281. Saltevo J., Vanhala M., Kautiainen H., Laakso M. Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood. Diab. Vasc Dis. Res. 2007, 4:328-331.
282. Sammut S., Bethus I., Goodall G., Muscat R. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol. Behav. 2002, 75:765-772.
283. Samuvel D.J., Jayanthi L.D., Bhat N.R., Ramamoorthy S. A role for p38 mitogen-activated protein kinase in the regulation of the serotonin transporter: evidence for distinct cellular mechanisms involved in transporter surface expression. J. Neurosci. 2005, 25:29-41.
284. Sanchez-Villegas A., Delgado-Rodriguez M., Alonso A., Schlatter J., Lahortiga F., Majem L.S., Martinez-Gonzalez M.A. Association of the Mediterranean dietary pattern with the incidence of depression: The Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Arch. Gen. Psychiatry 2009, 66:1090-1098.
285. Sas K., Robotka H., Toldi J., Vecsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 2007, 257:221-239.
286. Schaefer E.J., Gleason J.A., Dansinger M.L. Dietary fructose and glucose differentially affect lipid and glucose homeostasis. J. Nutr. 2009, 139:1257S-1262S.
287. Schaefer M., Schwaiger M., Garkisch A.S., Pich M., Hinzpeter A., Uebelhack R., Heinz A., van B.F., Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J. Hepatol. 2005, 42:793-798.
288. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. J. Neuropsychiatry Clin. Neurosci. 1995, 7:524-533.
289. Schlatter J., Ortuno F., Cervera-Enguix S. Monocytic parameters in patients with dysthymia versus major depression. J. Affect. Disord. 2004, 78:243-247.
290. Schmidt E.D., Aguilera G., Binnekade R., Tilders F.J. Single administration of interleukin-1 increased corticotropin releasing hormone and corticotropin releasing hormone-receptor mRNA in the hypothalamic paraventricular nucleus which paralleled long-lasting (weeks) sensitization to emotional stressors. Neuroscience 2003, 116:275-283.
291. Schramm T.M., Lawford B.R., Macdonald G.A., Cooksley W.G. Sertraline treatment of interferon-alfa-induced depressive disorder. Med. J. Aust. 2000, 173:359-361.
292. Schrocksnadel K., Wirleitner B., Winkler C., Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 2006, 364:82-90.
293. Schuster D.P. Changes in physiology with increasing fat mass. Semin. Pediatr. Surg. 2009, 18:126-135.
294. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 2002, 303:1-10.
295. Schwartz A.L., Thompson J.A., Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol. Nurs. Forum. 2002, 29:E85-E90.
296. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Cytokine production and serum proteins in depression. Scand. J. Immunol. 1995, 41:534-538.
297. Semiz S., Rota S., Ozdemir O., Ozdemir A., Kaptanoglu B. Are C-reactive protein and homocysteine cardiovascular risk factors in obese children and adolescents?. Pediatr. Int. 2008, 50:419-423.
298. Serhan C.N. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost. 2009, 7(Suppl 1):44-48.
299. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 2002, 196:1025-1037.
300. Shelton R.C. The molecular neurobiology of depression. Psychiatric Clin. North Am. 2007, 30:1-11.
301. Shelton R.C., Hal Manier D., Lewis D.A. Protein kinases A and C in post-mortem prefrontal cortex from persons with major depression and normal controls. Int. J. Neuropsychopharmacol. 2009, 12:1223-1232.
302. Shelton R.C., Liang S., Liang P., Chakrabarti A., Manier D.H., Sulser F. Differential expression of pentraxin 3 in fibroblasts from patients with major depression. Neuropsychopharmacology 2003, 29:129-132.
303. Shelton R.C., Manier D.H., Sulser F. cAMP-dependent protein kinase activity in major depression. Am. J. Psychiatry 1996, 153:1037-1042.
304. Shelton R.C., Manier D.H., Peterson C.S., Ellis T.C., Sulser F. Cyclic AMP-dependent protein kinase in subtypes of major depression and normal volunteers. Int. J. Neuropsychopharmcol. 1999, 2:187-192.
305. Shi W., Meininger C.J., Haynes T.E., Hatakeyama K., Wu G. Regulation of tetrahydrobiopterin synthesis and bioavailability in endothelial cells. Cell Biochem. Biophys. 2004, 41:415-434.
306. Shin J.Y., Kim S.Y., Jeung M.J., Eun S.H., Woo C.W., Yoon S.Y., Lee K.H. Serum adiponectin, C-reactive protein and TNF-alpha levels in obese Korean children. J. Pediatr. Endocrinol. Metab. 2008, 21:23-29.
307. Shoelson S.E., Herrero L., Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180.
308. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J. Clin. Invest. 2006, 116:1793-1801.
309. Shuto H., Kataoka Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997, 747:348-351.
310. Silswal N., Singh A.K., Aruna B., Mukhopadhyay S., Ghosh S., Ehtesham N.Z. Human resistin stimulates the pro-inflammatory cytokines TNF-[alpha] and IL-12 in macrophages by NF-[kappa]B-dependent pathway. Biochem. Biophysical. Res. Comm. 2005, 334:1092-1101.
311. Sluzewska A., Rybakowski J.K., Laciak M., Mackiewicz A., Sobieska M., Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann. N. Y. Acad. Sci. 1995, 762:474-476.
312. Somm E., Cettour-Rose P., Asensio C., Charollais A., Klein M., Theander-Carrillo C., Juge-Aubry C.E., Dayer J.M., Nicklin M.J., Meda P., Rohner-Jeanrenaud F., Meier C.A. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006, 49:387-393.
313. Somm E., Henrichot E., Pernin A., Juge-Aubry C.E., Muzzin P., Dayer J.M., Nicklin M.J., Meier C.A. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 2005, 54:3503-3509.
314. Song C., Dinan T., Leonard B.E. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord. 1994, 30:283-288.
315. Song C., Lin A., Bonaccorso S., Heide C., Verkerk R., Kenis G., Bosmans E., Scharpe S., Whelan A., Cosyns P., De J.R., Maes M. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 1998, 49:211-219.
316. Soygur H., Palaoglu O., Akarsu E.S., Cankurtaran E.S., Ozalp E., Turhan L., Ayhan I.H. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1242-1247.
317. Spetsieris P.G., Moeller J.R., Dhawan V., Ishikawa T., Eidelberg D. Visualizing the evolution of abnormal metabolic networks in the brain using PET. Computerized Med. Imaging Graphics 2005, 19:295-306.
318. Steene-Johannessen, J., Kolle, E., Reseland, J.E., Anderssen, S.A., Andersen, L.B. Waist circumference is related to low-grade inflammation in youth. Int. J Pediatr. Obes., in press.
319. Stenholm, S., Koster, A., Alley, D. E., Visser, M., Maggio, M., Harris, T. B., Egan, J.M., Bandinelli, S., Guralnik, J.M., Ferrucci, L. Adipocytokines and the metabolic syndrome among older persons with and without obesity - the InCHIANTI Study. Clin Endocrinol (Oxf), in press.
320. Stockinger B., Veldhoen M., Martin B. Th17 T cells: linking innate and adaptive immunity. Semin. Immunol. 2007, 19:353-361.
321. Stoll A.L., Severus W.E., Freeman M.P., Rueter S., Zboyan H.A., Diamond E., Cress K.K., Marangell L.B. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 1999, 56:407-412.
322. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002, 1:609-620.
323. Stuart W.I., de Heredia F.P., Wang B., Trayhurn P. Cellular hypoxia and adipose tissue dysfunction in obesity. Proc. Nutr. Soc. 2009, 68:370-377.
324. Sutherland J.P., McKinley B., Eckel R.H. The metabolic syndrome and inflammation. Metab. Syndr. Relat. Disord. 2004, 2:82-104.
325. Szuster-Ciesielska A., Tustanowska-Stachura A., Slotwinska M., Marmurowska-Michalowska H., Kandefer-Szerszen M. In vitro immunoregulatory effects of antidepressants in healthy volunteers. Pol. J. Pharmacol. 2003, 55:353-362.
326. Takeuchi T., Nakao M., Nomura K., Yano E. Association of metabolic syndrome with depression and anxiety in Japanese men. Diabetes Metab. 2009, 35:32-36.
327. Takeuchi T., Nakao M., Nomura K., Inoue M., Tsurugano S., Shinozaki Y., Yano E. Association of the metabolic syndrome with depression and anxiety in Japanese men: a 1-year cohort study. Diabetes Metab. Res. Rev. 2009, 25:762-767.
328. Takikawa O., Tagawa Y., Iwakura Y., Yoshida R., Truscott R.J. Interferon-gamma-dependent/independent expression of indoleamine 2,3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv. Exp. Med. Biol. 1999, 467:553-557.
329. Tam C.S., Clement K., Baur L.A., Tordjman J. Obesity and low-grade inflammation: a paediatric perspective. Obes. Rev. 2010, 11:118-126.
330. Tappy L., Le K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 2010, 90:23-46.
331. Tatro E.T., Everall I.P., Kaul M., Achim C.L. Modulation of glucocorticoid receptor nuclear translocation in neurons by immunophilins FKBP51 and FKBP52: Implications for major depressive disorder. Brain Res. 2009, 1286:1-12.
332. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O'Brien J.T. Increase in interleukin-1beta in late-life depression. Am. J. Psychiatry 2005, 162:175-177.
333. Tiemeier H., Hofman A., van Tuijl H.R., Kiliaan A.J., Meijer J., Breteler M.M. Inflammatory proteins and depression in the elderly. Epidemiology 2003, 14:103-107.
334. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat. Rev. Immunol. 2006, 6:772-783.
335. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 2008, 14:222-231.
336. Tisdale M.J. Cancer cachexia. Curr. Opin. Gastroenterol. 2009.
337. Tortosa A., Bes-Rastrollo M., Sanchez-Villegas A., Basterra-Gortari F.J., Nuñez-Cordoba J.M., Martinez-Gonzalez M.A. Mediterranean diet inversely associated with the incidence of metabolic syndrome. Diabetes Care 2007, 30:2957-2959.
338. Trayhurn P., Wang B., Wood I.S. Hypoxia and the endocrine and signalling role of white adipose tissue. Arch. Physiol. Biochem. 2008, 114:267-276.
339. Tsao C.W., Lin Y.S., Chen C.C., Bai C.H., Wu S.R. Cytokines and serotonin transporter in patients with major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006, 30:899-905.
340. Tsao C.W., Lin Y.S., Cheng J.T., Lin C.F., Wu H.T., Wu S.R., Tsai W.H. Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J. Psychopharmacol. 2008, 22:753-760.
341. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
342. Tyrovolas S., Lionis C., Zeimbekis A., Bountziouka V., Micheli M., Katsarou A., Papairakleous N., Metallinos G., Makri K., Polychronopoulos E., Panagiotakos D.B. Increased body mass and depressive symptomatology are associated with hypercholesterolemia, among elderly individuals; results from the MEDIS study. Lipids Health Dis. 2009, 8:10.
343. Tziomalos, K., Dimitroula, H.V., Katsiki, N., Savopoulos, C., Hatzitolios, A.I. Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. Mediators. Inflamm. in press.
344. Vamos E., Pardutz A., Klivenyi P., Toldi J., Vecsei L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J. Neurol. Sci. 2009, 283:21-27.
345. Van Gaal L.F., Mertens I.L., De Block C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444:875-880.
346. Vazquez-Vela M.E., Torres N., Tovar A.R. White adipose tissue as endocrine organ and its role in obesity. Arch. Med. Res. 2008, 39:715-728.
347. Vogelzangs N., Kritchevsky S.B., Beekman A.T.F., Newman A.B., Satterfield S., Simonsick E.M., Yaffe K., Harris T.B., Penninx B.W.J.H. Depressive symptoms and change in abdominal obesity in older persons. Arch. Gen. Psychiatry 2008, 65:1386-1393.
348. Vogelzangs N., Kritchevsky S.B., Beekman A.T., Brenes G.A., Newman A.B., Satterfield S., Yaffe K., Harris T.B., Penninx B.W. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J. Clin. Psychiatry. 2010, 71:391-399.
349. Wang Y., Lobstein T. Worldwide trends in childhood overweight and obesity. Int. J Pediatr. Obes. 2006, 1:11-25.
350. Warnberg J., Marcos A. Low-grade inflammation and the metabolic syndrome in children and adolescents. Curr. Opin. Lipidol. 2008, 19:11-15.
351. Weidenfeld J., Yirmiya R. Effects of bacterial endotoxin on the glucocorticoid feedback regulation of adrenocortical response to stress. Neuroimmunomodulation. 1996, 3:352-357.
352. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J. Clin. Invest. 2005, 115:1111-1119.
353. Wells J.C. The evolution of human fatness and susceptibility to obesity: an ethological approach. Biol. Rev. Camb. Philos. Soc. 2006, 81:183-205.
354. White J.S. Misconceptions about high-fructose corn syrup: is it uniquely responsible for obesity, reactive dicarbonyl compounds, and advanced glycation endproducts?. J. Nutr. 2009, 139:1219S-1227S.
355. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry. 2005, 10:538-544.
356. Wilborn C., Beckham J., Campbell B., Harvey T., Galbreath M., La B.P., Nassar E., Wismann J., Kreider R. Obesity: prevalence, theories, medical consequences, management, and research directions. J. Int. Soc. Sports Nutr. 2005, 2:4-31.
357. Winer J.C., Zern T.L., Taksali S.E., Dziura J., Cali A.M., Wollschlager M., Seyal A.A., Weiss R., Burgert T.S., Caprio S. Adiponectin in childhood and adolescent obesity and its association with inflammatory markers and components of the metabolic syndrome. J. Clin. Endocrinol. Metab. 2006, 91:4415-4423.
358. World Health Organization, 2010. Fact sheet: Obesity and overweight. http://www.who.int/mediacentre/factsheets/fs311/en/.
359. Wu F., Tyml K., Wilson J.X. iNOS expression requires NADPH oxidase-dependent redox signaling in microvascular endothelial cells. J. Cell. Physiol. 2008, 217:207-214.
360. Xu L.L., Warren M.K., Rose W.L., Gong W., Wang J.M. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukoc. Biol. 1996, 60:365-371.
361. Yang K., Xie G., Zhang Z., Wang C., Li W., Zhou W., Tang Y. Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression. Aust. N.Z. J Psychiatry 2007, 41:266-273.
362. Yaron I., Shirazi I., Judovich R., Levartovsky D., Caspi D., Yaron M. Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures. Arthritis Rheum. 1999, 42:2561-2568.
363. Ye J., Gao Z., Yin J., He Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1118-E1128.
364. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., Weihe E., Weidenfeld J. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001, 24:531-544.
365. Zadori D., Klivenyi P., Vamos E., Fulop F., Toldi J., Vecsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J. Neural. Transm. 2009, 116:1403-1409.
366. Zautra A.J., Yocum D.C., Villanueva I., Smith B., Davis M.C., Attrep J., Irwin M. Immune activation and depression in women with rheumatoid arthritis. J. Rheumatol. 2004, 31:457-463.
367. Zhu C.B., Carneiro A.M., Dostmann W.R., Hewlett W.A., Blakely R.D. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J. Biol. Chem. 2005, 280:15649-15658.
368. Zhu J., Bengtsson B.O., Mix E., Ekerling L., Thorell L.H., Olsson T., Link H. Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. J. Autoimmun. 1998, 11:319-327.
369. Zhu J., Bengtsson B.O., Mix E., Thorell L.H., Olsson T., Link H. Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN). Immunopharmacology 1994, 27:225-244.